News >

Expert Highlights CAR T-Cell Breakthroughs

Angelica Welch
Published: Wednesday, Nov 01, 2017

David Maloney, MD, PhD

David Maloney, MD, PhD
The oncology community saw the first FDA approval of a chimeric antigen receptor (CAR) T-cell therapy in August 2017, when tisagenlecleucel (Kymriah) was approved for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refectory or in second or later relapse.

that was conducted between the time of these 2 approvals, David G. Maloney, MD, PhD, a member of the Clinical Research Division, Fred Hutchinson Cancer Research Center, discussed the progress made with CAR T cells, as well as the challenges that still exist in the use of this therapy.

OncLive: Can you discuss the success that has been seen with CAR T-cell therapy in ALL?

Maloney: We are doing most of our research in CAR T cells, and that is what I am the most interested in. The process for a CAR gene-modified T cell is that we take out a patient’s normal resting T cells and separate them in the laboratory into different populations and transduce them with a lentivirus expressing a CAR. That CAR gene now makes an antibody transgene on the cell surface that can then bind the T cell to whatever the target is. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x